U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Improper merging of impax cardiovascular results management (rm) reports causes the signed report to become unavailable.
조치
AGFA Healthcare sent an "URGENT FIELD SAFETY NOTICE" letter dated May 27, 2011, via Fed Ex to all affected customers. The letter identified the product, the problem, and the action to be taken by the customer. Customers were instructed not to carry out a merge post finalization of an RM reports. If it is necessary to modify a finalized report, AGFA recommends that they make the modification through one of the following actions:
Amend the report through the RM interface, or
Call AGFA Service to change the status of the report to "preliminary" and then proceed with the finalization of the report.
AGFA issued an Acknowledgment, via FAX- Back that the information was received and understood to affected customers.
For any questions customers were instructed to contact their AGFA Healthcare Service at 877-777-2432.
Worldwide Distribution - USA (nationwide) and Canada
제품 설명
IMPAX Cardiovascular Results Management (RM) Software Versions RM 2.04.37.04 to RM 7.8 SU2 || The IMPAX Cardiovascular suite is a cardiovascular information system providing image archiving and image display and modality study-specific structured reporting.